解放军医学院学报2025，Vol.46Issue(3)：287-290,后插1,5.DOI:10.12435/j.issn.2095-5227.2025.24082603
硫酸黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯耐药的肠杆菌及铜绿假单胞菌感染的疗效比较
Comparison of effect between colistin sulfate and ceftazidime-avibactam for treating infections caused by carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa
康奕欣 1姚雪鑫 2戈艳蕾 2崔俊昌1
作者信息
- 1. 解放军总医院第八医学中心呼吸与危重症医学部,北京 100853||南开大学医学院,天津 300074
- 2. 华北理工大学附属医院呼吸内科,河北 唐山 063099
- 折叠
摘要
Abstract
Background Carbapenem-resistant Enterobacteriaceae(CRE)and carbapenem-resistant Pseudomonas aeruginosa(CRPA)infections have been widely spreading in our country in recent years,posing a great challenge to clinical work.Colistin sulfate and ceftazidime-avibactam are the last resort for treating CRE and CRPA.Objective To compare the effect of colistin sulfate and ceftazidime-avibactam for treating CRE and CRPA infections.Methods Basic information of patients with CRE or CRPA infections treated with colistin sulfate or ceftazidime-avibactam and outcomes after anti-infective treatment were collected,respectively.Results A total of 82 patients were included in this study,with 42 cases in the colistin sulfate group and 40 cases in the ceftazidime-avibactam group.The median age in the colistin sulfate group was 83.0(62.8-91.0)years,and 31 cases were male.In the ceftazidime-avibactam group,the median age was 80.5(56.5-91.8)years,with 29 males.There was no statistical difference in the basic information between the colistin sulfate group and the ceftazidime-avibactam group.Regarding outcomes,compared with the ceftazidime-avibactam group,the clinical cure rate and 7-day survival rate in the colistin sulfate group were 50%vs 40%,and 71.4%vs 62.5%,without significant difference(P＞0.05,respectively).Concerning adverse effects,no statistically significant difference was observed in the incidence of renal injury between the two groups.Conclusion The effectiveness of colistin sulfate in treating CRE or CRPA infections is similar to ceftazidime-avibactam,with no significant differences.In clinical practice,specific drugs can be selected for anti-infective treatment based on drug availability.关键词
头孢他啶-阿维巴坦/硫酸黏菌素/耐碳青霉烯肠杆菌/耐碳青霉烯铜绿假单胞菌Key words
ceftazidime-avibactam/colistin sulfate/carbapenem-resistant Enterobacteriaceae/carbapenem-resistant Pseudomonas aeruginosa分类
医药卫生引用本文复制引用
康奕欣,姚雪鑫,戈艳蕾,崔俊昌..硫酸黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯耐药的肠杆菌及铜绿假单胞菌感染的疗效比较[J].解放军医学院学报,2025,46(3):287-290,后插1,5.
